ASCO 2022: Immediate Options for Endocrine Therapy-Refractory Patients With HER2-Low Metastatic Breast Cancer ASCO 2022: Immediate Options for Endocrine Therapy-Refractory Patients With HER2-Low Metastatic Breast Cancer
Tarah J. Ballinger, MD, discusses the implications of the DESTINY-Breast 04 trial and the immediate impact that it will have on the lives of her patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news

Adding Opdivo in First-Line Shows Promise in HER2+ Esophagogastric Cancer
(MedPage Today) -- A combination of the PD-1 inhibitor nivolumab (Opdivo) plus trastuzumab and chemotherapy (mFOLFOX6) was effective as first-line therapy for patients with HER2 (ERBB2)-positive esophagogastric adenocarcinoma, according to results... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 23, 2022 Category: Hematology Source Type: news

AstraZeneca breast cancer drug that slows disease progression approved for earlier use
A breast cancer drug previously available as a treatment for certain later-stage tumors has been approved for earlier use in the United States after a phase 3 trial showed it reduced the risk of disease progression or death by 72% compared to another common treatment for patients with HER2 positive metastatic breast cancer. “This is an important day for the breast cancer community,” said Catherine Ormerod, executive vice president, Strategy and Mission, Living Beyond Breast Cancer. Enhertu… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 8, 2022 Category: American Health Authors: Anne Stych Source Type: news

Women With HER2+ Metastatic Breast Cancer Are Living Longer Women With HER2+ Metastatic Breast Cancer Are Living Longer
An analysis of overall survival from 2010 to 2018 shows women with metastatic HER2+ breast cancer are generally living longer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Enhertu Benefit in HER2-Low Breast Cancer:'Practice Changing'Enhertu Benefit in HER2-Low Breast Cancer:'Practice Changing '
Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, had improved progression-free survival with trastuzumab deruxtecan (Enhertu).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Sacituzumab a'Step Forward' in Breast Cancer Unmet Need Sacituzumab a'Step Forward' in Breast Cancer Unmet Need
Sacituzumab govitecan (Trodelvy) beat chemotherapy in patients with heavily pretreated endocrine resistant HR+/HER2- advanced breast cancer, who represent a ' great clinical unmet need, ' says expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Endocrine Switch Plus Ribociclib Active in Post-CDK4/6 Inhibitor Progression
(MedPage Today) -- CHICAGO -- Progression-free survival (PFS) in advanced hormone receptor (HR)-positive/HER2-negative breast cancer improved significantly in patients who received ribociclib (Kisqali) and a different endocrine therapy after... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2022 Category: Hematology Source Type: news

Capivasertib-Fulvestrant Combo Ups Survival in ER+/HER2- Metastatic Breast Cancer
(MedPage Today) -- CHICAGO -- Adding investigational capivasertib to fulvestrant extended survival in patients with aromatase inhibitor-resistant estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, according to updated results... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2022 Category: Hematology Source Type: news

Trastuzumab Deruxtecan Ushers in New Treatment Era for HER2-Low Breast Cancer
(MedPage Today) -- CHICAGO -- Patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan (Enhertu) achieved significant improvements in survival compared with those treated with chemotherapy alone, according to results... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2022 Category: Hematology Source Type: news

Sacituzumab Govitecan Boosts PFS in Late-Line HR+/HER2- Metastatic Breast Cancer
(MedPage Today) -- CHICAGO -- Patients with heavily pretreated metastatic breast cancer experienced a progression-free survival (PFS) benefit with sacituzumab govitecan-hziy (Trodelvy) versus physician's choice of chemotherapy, according to the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2022 Category: Hematology Source Type: news

Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer
(MedPage Today) -- Adding mTOR inhibitor everolimus (Afinitor) to adjuvant endocrine therapy failed to improve disease-free survival (DFS) in high-risk hormone receptor-positive/HER2-negative (HR+/HER2-), a large randomized trial showed. Three... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 2, 2022 Category: Hematology Source Type: news

Significance of HER2-low Expression in Early Breast Cancer Significance of HER2-low Expression in Early Breast Cancer
A better understanding of low HER2 expression in early breast cancer could lead to more targeted treatments and improved survival.Breast Cancer Research (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 31, 2022 Category: Surgery Tags: Hematology-Oncology Journal Article Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news